Table 4

Association of hepatocyte growth factor and subclinical and clinical atherosclerotic diseases by baseline age grouping

Examination 1, age 45–64 years (n=3790)Examination 1, age 65–84 years (n=2951)
Beta (SE)p ValueBeta (SE)p Value
CAC, Agatston score
 Model 156 (8.3)<0.00161 (13)<0.001
 Model 227 (8.8)0.00237 (14)0.008
Common carotid IMT, mm
 Model 10.015 (0.003)<0.0010.001 (0.004)0.75
 Model 20.003 (0.003)0.27−0.005 (0.004)0.17
Internal carotid IMT, mm
 Model 10.054 (0.008)<0.0010.065 (0.014)<0.001
 Model 20.025 (0.008)0.0020.044 (0.014)0.002
OR (95% CI) p Value OR (95% CI) p Value
Presence of plaque
 Model 11.23 (1.14 to 1.33)<0.0011.16 (1.07 to 1.26)<0.001
 Model 21.10 (1.01 to 1.19)0.0281.11 (1.02 to 1.21)0.02
Number of CHD events193336
Total person-years43 37929 454
Crude CHD rate, per 1000 person-years4.411.4
HR (95% CI) p Value HR (95% CI) p Value
Time to CHD
 Model 11.52 (1.35 to 1.72)<0.0011.18 (1.06 to 1.31)0.002
 Model 21.32 (1.15 to 1.51)<0.0011.12 (1.01 to 1.26)0.04
  • Model 1 = age, sex and race/ethnicity.

  • Model 2 = age, sex, bodyModel 1 = age, sex and race/ethnicity.

  • Model 2 = age, sex, body mass index, systolic blood pressure, hypertension treatment, total cholesterol, high-density lipoprotein cholesterol, smoking and diabetes status and race/ethnicity.

  • CAC, coronary artery calcium; CHD, coronary heart disease; IMT, intima-media thickness.